CRF Meeting will Feature Research Updates and Latest Technologies for the Treatment of Valvular Heart Disease


TVT 2016 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts. The agenda is now available online at:

Sessions showcasing the latest research will focus on updates and new insights from transcatheter valve trials and registries in lower surgical risk patients. Among the trials that will be discussed are: 

Highlights From PARTNER 2A in Intermediate-Risk Patients

Michael J. Mack

Updates From NOTION: The First All-Comer TAVR Trial

Lars Sondergaard

Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients

Vinod H. Thourani

Updates From SURTAVI in Intermediate-Risk Patients

Jeffrey J. Popma

Updates From the UK All-Comer TAVR Study

Neil E. Moat

Study Design for the EVOLUT R Low-Risk Trial

Jeffrey J. Popma

Study Design for the PARTNER 3 Low-Risk Trial

Martin B. Leon

The meeting will also examine:

  • Direct and indirect annuloplasty devices  
  • New access site management systems (transfemoral and transapical)
  • New TAVR accessories including balloon valvuloplasty devices, access site closure technologies, guidewires and sheath technologies, cerebral embolic protection technologies, and imaging systems


Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.


June 16-18, 2016


Sheraton Grand Chicago

301 East North Water Street

Chicago, Illinois


The course directors for TVT 2016 are:

Martin B. Leon, MD

NewYork-Presbyterian Hospital/Columbia University Medical Center

Francesco Maisano, MD

UniversitätsSpital Zürich

Nicolo Piazza, MD, PhD

McGill University Health Center

Mark Reisman, MD

University of Washington Medical Center/Regional Heart Center

Gregg W. Stone, MD

New York-Presbyterian Hospital/Columbia University Medical Center

John G. Webb, MD

St. Paul's Hospital


Media may apply for registration by emailing

Can’t attend in person? Reporters are eligible for access to Virtual TVT which provides live and on-demand viewing of the meeting sessions.

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Senior Manager, External Relations
Tel: 646-434-4608